Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, recently sat down for an interview with Nasdaq’s Kristina Ayanian at their New York headquarters. In the interview, Kevin explained how Ossium is leveraging its organ donor-derived bone marrow platform to improve the accessibility and quality of leukemia treatments today and develop innovative therapies for organ rejection and orthopedic applications tomorrow.

See the full interview below.